Chemotherapy for Prostate Cancer: Docetaxel & Cabazitaxel Guide

What is chemotherapy for prostate cancer?

Chemotherapy uses drugs to kill rapidly dividing cancer cells throughout the body. Unlike hormone therapy (which targets testosterone), chemotherapy directly attacks cancer cells regardless of hormone sensitivity.

For prostate cancer, chemotherapy is used for metastatic disease (cancer that has spread beyond the prostate) that has become resistant to hormone therapy or as initial treatment for high-volume metastatic disease.

When is chemotherapy used?

Chemotherapy is used in two main settings:

1. Metastatic castration-sensitive prostate cancer (mHSPC):

• High-volume disease: Docetaxel + ADT improves survival (CHAARTED trial)
• High-volume = visceral metastases or ≥4 bone metastases (1 outside spine/pelvis)
• Added to ADT (hormone therapy) at the start of treatment

2. Metastatic castration-resistant prostate cancer (mCRPC):

• First-line: Docetaxel (TAX327 trial) – improves survival and quality of life
• Second-line: Cabazitaxel (after docetaxel failure) – TROPIC trial

When chemotherapy is NOT used:

• Localized prostate cancer (surgery or radiation is curative)
• Biochemical recurrence without metastases (ADT alone is preferred)
• Low-volume mHSPC (some trials show no benefit)

Docetaxel – first-line chemotherapy

Docetaxel (Taxotere) is a taxane chemotherapy that inhibits microtubule depolymerisation, preventing cancer cell division. It is the standard first-line chemotherapy for metastatic prostate cancer.

Regimen:

• Dose: 75 mg/m² IV every 3 weeks
• Pre-medications: Dexamethasone (reduce fluid retention, allergic reactions)
• Number of cycles: 6-10 cycles (typically 10 for mHSPC, 6-10 for mCRPC)
• Administration: IV infusion over 1 hour

Key trials:

• TAX327 (2004): Docetaxel improved survival in mCRPC (18.9 vs. 16.5 months)
• CHAARTED (2015): Docetaxel + ADT improved survival in high-volume mHSPC (51.2 vs. 34.4 months)
• STAMPEDE (2016): Docetaxel + ADT improved survival in newly diagnosed metastatic prostate cancer

Cabazitaxel – second-line after docetaxel

Cabazitaxel (Jevtana) is a next-generation taxane designed to overcome docetaxel resistance. It is used for metastatic castration-resistant prostate cancer (mCRPC) that has progressed on docetaxel.

Regimen:

• Dose: 20-25 mg/m² IV every 3 weeks
• Pre-medications: Antihistamines, corticosteroids (reduce allergic reactions)
• Number of cycles: 6-10 cycles (as tolerated)

Key trials:

• TROPIC (2010): Cabazitaxel improved survival in mCRPC post-docetaxel (15.1 vs. 12.7 months)
• PROSELICA (2017): Lower dose (20 mg/m²) equally effective with fewer side effects

Effectiveness – survival benefits

Chemotherapy significantly improves survival in metastatic prostate cancer:

• mCRPC (post-ADT failure): Docetaxel improves median survival by 2-3 months (TAX327)
• High-volume mHSPC: Docetaxel + ADT improves median survival by 13-17 months (CHAARTED)
• Post-docetaxel mCRPC: Cabazitaxel improves median survival by 2-3 months (TROPIC)

PSA response:

• 50% PSA decline: 45-50% with docetaxel
• PSA decline correlates with improved survival

Side effects – neutropenia, fatigue, neuropathy, alopecia

Docetaxel and cabazitaxel have similar side effect profiles:

Common side effects (30-50%):

• Neutropenia (low white blood cells): Increased infection risk – most serious
• Fatigue: Cumulative, peaks after 3-4 cycles
• Alopecia (hair loss): Temporary – hair regrows after treatment
• Nausea and diarrhoea: Usually mild

Less common but serious (10-20%):

• Febrile neutropenia (fever with low WBC): Requires hospitalisation
• Peripheral neuropathy: Numbness/tingling in hands/feet (cumulative, dose-limiting)
• Fluid retention: Prevented by dexamethasone pre-medication
• Fatigue: Most bothersome for many patients

Cabazitaxel-specific:

• Higher risk of diarrhoea and neutropenia than docetaxel
• Lower risk of neuropathy

Managing side effects – growth factors, supportive care

Neutropenia prevention:

• G-CSF (filgrastim, pegfilgrastim): Growth factor injections to boost white blood cells
• Used for patients with high risk of febrile neutropenia (elderly, poor performance status)
• Prophylactic antibiotics (rarely used)

Fatigue management:

• Regular light exercise (walking) – most effective
• Energy conservation (rest before fatigue sets in)
• Good nutrition and hydration

Peripheral neuropathy:

• Dose reduction or delay of chemotherapy
• Gabapentin or pregabalin for neuropathic pain
• Physical therapy for balance issues

Nausea and diarrhoea:

• Anti-emetics (ondansetron, prochlorperazine) before infusion
• Loperamide for diarrhoea
• Hydration (oral or IV fluids if severe)

Alopecia (hair loss):

• Temporary – hair regrows 2-3 months after treatment ends
• Cooling caps may reduce hair loss (not always effective)

What to expect during chemotherapy

Before each cycle:

• Blood tests (CBC, liver function, kidney function)
• Physical exam and symptom review
• Dose adjustment based on side effects

Day of infusion:

• Pre-medications (dexamethasone, antihistamines)
• IV infusion over 1 hour
• Observation for allergic reactions (rare)
• Total clinic time: 2-4 hours

After infusion (days 1-7):

• Fatigue peaks days 3-5
• Nadir (lowest white blood cells) days 7-10
• Monitor for fever (call immediately if >100.4°F)

Between cycles (days 8-21):

• Gradual recovery of energy and blood counts
• Repeat every 3 weeks for 6-10 cycles

Interactive FAQ – Chemotherapy for prostate cancer

---

Disclaimer: This information is for educational purposes. Chemotherapy decisions should be made with a medical oncologist. Consult a specialist at Vivekananda Hospital.